3rd Quarter - Report
BROWN RUDNICK LLP for APOTEX CORPORATION
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues relating to Risk Evaluation and Mitigation Strategy programs; Generic Drug User Fee Amendments of 2012 (GDUFA); Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER BOWLIN | — |
| LISA LAYMAN | — |
| HENRY W MENN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.